These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
609 related articles for article (PubMed ID: 26420955)
1. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. Mori S; Fujiyama S World J Gastroenterol; 2015 Sep; 21(36):10274-89. PubMed ID: 26420955 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Lee YH; Bae SC; Song GG Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Lee YH; Bae SC; Song GG Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095 [TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649 [TBL] [Abstract][Full Text] [Related]
5. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442 [TBL] [Abstract][Full Text] [Related]
6. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305 [TBL] [Abstract][Full Text] [Related]
7. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752 [TBL] [Abstract][Full Text] [Related]
8. Risk of rituximab-induced hepatitis B flare after antiviral discontinuation in rheumatic patients with chronic hepatitis B virus. Lan TY; Chang TW; Tseng TC; Lee TJ; Kao JH; Cheng CF; Huang SC; Shen CY; Lu CH; Yang HC; Li KJ; Hsieh SC Clin Exp Rheumatol; 2024 Sep; 42(9):1830-1837. PubMed ID: 38855955 [TBL] [Abstract][Full Text] [Related]
9. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. Ahn SS; Jung SM; Song JJ; Park YB; Park JY; Lee SW Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409 [TBL] [Abstract][Full Text] [Related]
10. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center. Ito S Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133 [TBL] [Abstract][Full Text] [Related]
11. Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents. Ghang B; Lee D; Hwang I; Lee CK; Yoo B; Kim YG Clin Exp Rheumatol; 2018; 36(1):170. PubMed ID: 29352838 [No Abstract] [Full Text] [Related]
12. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494 [TBL] [Abstract][Full Text] [Related]
13. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932 [TBL] [Abstract][Full Text] [Related]
14. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789 [TBL] [Abstract][Full Text] [Related]
15. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. Moghoofei M; Mostafaei S; Ashraf-Ganjouei A; Kavosi H; Mahmoudi M Microb Pathog; 2018 Jan; 114():436-443. PubMed ID: 29223453 [TBL] [Abstract][Full Text] [Related]
16. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. Su YC; Lin PC; Yu HC; Wu CC Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351 [TBL] [Abstract][Full Text] [Related]
17. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242 [TBL] [Abstract][Full Text] [Related]
18. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383 [TBL] [Abstract][Full Text] [Related]
19. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. Su J; Long L; Zou K Clin Rheumatol; 2018 Dec; 37(12):3201-3214. PubMed ID: 29637482 [TBL] [Abstract][Full Text] [Related]
20. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV. Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]